The estimated Net Worth of Kamil Ali Jackson is at least $4.57 Million dollars as of 3 January 2022. Ms. Jackson owns over 45,518 units of Aclaris Therapeutics Inc stock worth over $189,053 and over the last 9 years she sold ACRS stock worth over $1,657,711. In addition, she makes $2,725,200 as Co-Founder, Chief Compliance Officer, Secretary, and Chief Legal Officer at Aclaris Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Jackson ACRS stock SEC Form 4 insiders trading
Kamil has made over 20 trades of the Aclaris Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 45,518 units of ACRS stock worth $53,711 on 3 January 2022.
The largest trade she's ever made was exercising 45,518 units of Aclaris Therapeutics Inc stock on 3 January 2022 worth over $53,711. On average, Kamil trades about 6,791 units every 45 days since 2015. As of 3 January 2022 she still owns at least 160,214 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Ms. Jackson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kamil Ali-Jackson biography
Kamil Ali-Jackson J.D. serves as Co-Founder, Chief Compliance Officer, Secretary, Chief Legal Officer of the Company. Ms. Ali-Jackson also serves as our Chief Compliance Officer and Secretary. In addition, Ms. Ali-Jackson has served as the Chief Legal Officer of NST, LLC and NST Consulting, LLC since 2013 and 2014, respectively. From 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Ltd., in 2013, Ms. Ali-Jackson served as Chief Legal Officer, Chief Compliance Officer and Secretary of Ceptaris Therapeutics, Inc., a biotechnology company. From 2010 to 2011, she was a consultant to a private specialty pharmaceutical company. From 2006 to 2010, she served as General Counsel and Secretary of Ception Therapeutics, Inc., a biotechnology company that was acquired by Cephalon, Inc. Previously, Ms. Ali-Jackson served as legal counsel and a licensing business executive for a number of pharmaceutical companies, including Merck & Co., Inc., Dr. Reddy’s Laboratories Inc. and Endo Pharmaceuticals, Inc. Ms. Ali-Jackson received a J.D. degree from Harvard Law School and an A.B. degree in Politics from Princeton University. Ms. Ali-Jackson currently serves on the board of directors, audit committee, compensation committee and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly held company, and the board of trustees of Rosemont College, a private liberal arts college in Pennsylvania.
What is the salary of Kamil Jackson?
As the Co-Founder, Chief Compliance Officer, Secretary, and Chief Legal Officer of Aclaris Therapeutics Inc, the total compensation of Kamil Jackson at Aclaris Therapeutics Inc is $2,725,200. There are 1 executives at Aclaris Therapeutics Inc getting paid more, with Neal Walker having the highest compensation of $3,150,020.
How old is Kamil Jackson?
Kamil Jackson is 61, she's been the Co-Founder, Chief Compliance Officer, Secretary, and Chief Legal Officer of Aclaris Therapeutics Inc since 2016. There are 2 older and 12 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.
What's Kamil Jackson's mailing address?
Kamil's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Insiders trading at Aclaris Therapeutics Inc
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol..., and Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
What does Aclaris Therapeutics Inc do?
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
What does Aclaris Therapeutics Inc's logo look like?
Complete history of Ms. Jackson stock trades at Aclaris Therapeutics Inc, Rigel Pharmaceuticals, and PDS Biotechnology
Aclaris Therapeutics Inc executives and stock owners
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Neal Walker,
President, Chief Executive Officer, Co-Founder, Director -
Kamil Ali-Jackson,
Co-Founder, Chief Compliance Officer, Secretary, Chief Legal Officer -
David Gordon,
Chief Medical Officer -
Frank Ruffo,
Co-Founder, Chief Financial Officer -
Dr. Neal S. Walker D.O.,
Co-Founder, CEO, Pres & Director -
Frank Ruffo,
Co-Founder, CFO & Treasurer -
Christopher Molineaux,
Independent Director -
Bryan Reasons,
Independent Director -
Andrew Powell,
Independent Director -
Anand Mehra,
Independent Director -
William Humphries,
Independent Director -
Andrew Schiff,
Independent Director -
Maxine Gowen,
Independent Director -
Vincent Milano,
Director -
James Loerop,
Chief Bus. Officer -
Dr. Paul S. Changelian Ph.D.,
Sr. VP of Biology -
Spencer Brown J.D.,
Sr. VP of Legal Affairs & Compliance Officer -
Dr. Joseph Monahan,
Chief Scientific Officer -
Rick Bierly,
Director -
Ventures Vii, Llc Vivo Vent...,
-
Stephen A. Tullman,
Director -
Albert Cha,
Director -
Stuart Shanler,
Chief Scientific Officer -
Capital Management, Llc Kol...,
-
Christopher Powala,
Chief Operating Officer -
Llc Fmr,
10% owner -
James E Deerfield Mgmt L.P....,
-
Capital Management Iii, Llc...,
-
Brett Fair,
Chief Commercial Officer -
Capital Management, Llc Kol...,
-
Venture Partners Viii, L.P....,
-
Gail Cawkwell,
Chief Medical Officer -
Joseph Monahan,
Chief Scientific Officer -
Douglas J. Manion,
Pres and CEO -
James Loerop,
Chief Business Officer -
Braden Michael Leonard,
-
Kevin Balthaser,
Chief Financial Officer